Daily irradiation versus irradiation at two- to three-day intervals in stereotactic radiotherapy for patients with 1-5 brain metastases: study protocol for a multicenter open-label randomized phase II trial
Authors:
- Natsuo TomitaNatsuo Tomita
- Hiromichi IshiyamaHIHiromichi Ishiyama
- Chiyoko MakitaCMChiyoko Makita
- Yukihiko OhshimaYOYukihiko Ohshima
- Aiko NagaiANAiko Nagai
- Fumiya BabaFBFumiya Baba
- Mayu KunoMKMayu Kuno
- Shinya OtsukaSOShinya Otsuka
- Takuhito KondoTKTakuhito Kondo
- Chikao SugieCSChikao Sugie
- Tatsuya KawaiTKTatsuya Kawai
- Taiki TakaokaTTTaiki Takaoka
Open Access
- 5 December 2022
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-8
Abstract
Background: Radiobiological daily changes within tumors are considered to be quite different between stereotactic radiotherapy (SRT) (e.g., 50 Gy in 4 fractions) and conventional radiotherapy (e.g., 60 Gy in 30 fractions). We aim to assess the optimal interval of irradiation in SRT and compare outcomes of daily irradiation with irradiation at two- to three-day intervals in SRT for patients with one to five brain metastases (BM). Methods: This study is conducted as a multicenter open-label randomized phase II trial. Patients aged 20 or older with one to five BM, less than 3.0 cm diameter, and Karnofsky Performance Status ≥70 are eligible. A total of 70 eligible patients will be enrolled. After stratifying by the number of BMs (1, 2 vs. 3–5) and diameter of the largest tumor (< 2 cm vs. ≥ 2 cm), we randomly assigned patients (1:1) to receive daily irradiation (Arm 1), or irradiation at two- to three-day intervals (Arm 2). Both arms are performed with total dose of 27-30 Gy in 3 fractions. The primary endpoint is an intracranial local control rate, defined as intracranial local control at initially treated sites. We use a randomized phase II screening design with a two-sided α of 0∙20. The phase II trial is positive with p < 0.20. All analyses are intention to treat. This study is registered with the UMIN-clinical trials registry, number UMIN000048728. Discussion: This study will provide an assessment of the impact of SRT interval on local control, survival, and toxicity for patients with 1–5 BM. The trial is ongoing and is recruiting now. Trial registration: UMIN000048728. Date of registration: August 23, 2022. https://center6.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000055515.Keywords
This publication has 14 references indexed in Scilit:
- Efficacy of stereotactic radiotherapy for brain metastases using dynamic jaws technology in the helical tomotherapy systemBritish Journal of Radiology, 2016
- Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trialsThe Lancet Oncology, 2015
- The Tumor Radiobiology of SRS and SBRT: Are More Than the 5 Rs Involved?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Helical Tomotherapy for Brain Metastases: Dosimetric Evaluation of Treatment Plans and Early Clinical ResultsTechnology in Cancer Research & Treatment, 2008
- Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening TrialsJournal of Clinical Oncology, 2005
- Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcomeRadiotherapy and Oncology, 1999
- Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neckRadiotherapy and Oncology, 1996
- Tumor oxygenation and reoxygenation during radiation theraphy: Their importance in predicting tumor responseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1986
- Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenationBritish Journal of Radiology, 1979
- The Concentration of Oxygen Dissolved in Tissues at the Time of Irradiation as a Factor in RadiotherapyBritish Journal of Radiology, 1953